SILENCE THERAPEUTICS PLC's ticker is SLN and the CUSIP is 82686Q101. A total of 23 filers reported holding SILENCE THERAPEUTICS PLC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,740,000 | +80.7% | 4,057,932 | -1.5% | 0.76% | +91.2% |
| Q2 2023 | $18,668,445 | -9.8% | 4,120,416 | +4.1% | 0.40% | -13.0% |
| Q1 2023 | $20,689,170 | -59.1% | 3,959,101 | +2.2% | 0.46% | -64.8% |
| Q4 2022 | $50,594,057 | +41.6% | 3,875,734 | -0.5% | 1.29% | +24.7% |
| Q3 2022 | $35,721,000 | -6.4% | 3,896,595 | +3.5% | 1.04% | -29.3% |
| Q2 2022 | $38,166,000 | -31.5% | 3,766,369 | +3.7% | 1.47% | -27.9% |
| Q1 2022 | $55,692,000 | -32.9% | 3,632,234 | +4.6% | 2.04% | -37.2% |
| Q4 2021 | $82,959,000 | +678.7% | 3,472,521 | +480.6% | 3.24% | +593.4% |
| Q3 2021 | $10,653,000 | -50.7% | 598,141 | -34.5% | 0.47% | -45.6% |
| Q2 2021 | $21,608,000 | -11.5% | 913,134 | -23.8% | 0.86% | -4.5% |
| Q1 2021 | $24,425,000 | +140.3% | 1,198,141 | +121.9% | 0.90% | +84.0% |
| Q4 2020 | $10,166,000 | +25.5% | 540,000 | 0.0% | 0.49% | -7.2% |
| Q3 2020 | $8,103,000 | – | 540,000 | – | 0.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 1,312,233 | $12,886,128 | 11.68% |
| M28 Capital Management LP | 363,800 | $3,572,516 | 4.10% |
| TCG Crossover Management, LLC | 2,104,875 | $20,669,873 | 3.04% |
| Lombard Odier Asset Management (Europe) Ltd | 3,443,912 | $33,819,216 | 1.73% |
| Lynx1 Capital Management LP | 235,787 | $2,315,428 | 1.53% |
| Artal Group S.A. | 2,500,000 | $24,550 | 1.05% |
| Lombard Odier Asset Management (USA) Corp | 4,057,932 | $33,740,000 | 0.76% |
| Deep Track Capital, LP | 1,951,580 | $19,164,516 | 0.74% |
| Frazier Life Sciences Management, L.P. | 881,173 | $8,661,931 | 0.58% |
| BVF INC/IL | 1,508,416 | $14,827,729 | 0.40% |